相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Regulatory policy for the development of targeted therapies for low-frequency molecular subtypes of disease
Robert N. Schuck et al.
NATURE REVIEWS DRUG DISCOVERY (2018)
Cerebrospinal fluid and vitreous body exposure to orally administered tafamidis in hereditary ATTRV30M (p.TTRV50M) amyloidosis patients
Cecilia Monteiro et al.
AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS (2018)
Plasminogen activation triggers transthyretin amyloidogenesis in vitro
P. Patrizia Mangione et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2018)
Failure of Tafamidis to Halt Progression of Ala36Pro TTR Oculomeningovascular Amyloidosis
Fabrizio Salvi et al.
JOURNAL OF STROKE & CEREBROVASCULAR DISEASES (2018)
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
D. Adams et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis
M. D. Benson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Understanding and misunderstanding randomized controlled trials
Angus Deaton et al.
SOCIAL SCIENCE & MEDICINE (2018)
Reflections on Randomized Control Trials
Angus Deaton et al.
SOCIAL SCIENCE & MEDICINE (2018)
Failure of Tafamidis to Halt Progression of Ala36Pro TTR Oculomeningovascular Amyloidosis
Fabrizio Salvi et al.
JOURNAL OF STROKE & CEREBROVASCULAR DISEASES (2018)
Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy
Mathew S. Maurer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Peptide probes detect misfolded transthyretin oligomers in plasma of hereditary amyloidosis patients
Joseph D. Schonhoft et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
The Effects of 2′-O-Methoxyethyl Containing Antisense Oligonucleotides on Platelets in Human Clinical Trials
Stanley T. Crooke et al.
NUCLEIC ACID THERAPEUTICS (2017)
Trial design and rationale for APOLLO, a Phase 3, placebo-controlled study of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy
David Adams et al.
BMC NEUROLOGY (2017)
CSP-1103 (CHF5074) stabilizes human transthyretin in healthy human subjects
Lixia Qiang et al.
AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS (2017)
Efficiency of silencing RNA for removal of transthyretin V30M in a TTR leptomeningeal animal model
Paula Goncalves et al.
AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS (2016)
Suppressing transthyretin production in mice, monkeys and humans using 2nd-Generation antisense oligonucleotides
Elizabeth J. Ackermann et al.
AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS (2016)
The Kinetic Stability of a Full-Length Antibody Light Chain Dimer Determines whether Endoproteolysis Can Release Amyloidogenic Variable Domains
Gareth J. Morgan et al.
JOURNAL OF MOLECULAR BIOLOGY (2016)
Monitoring effectiveness and safety of Tafamidis in transthyretin amyloidosis in Italy: a longitudinal multicenter study in a non-endemic area
A. Cortese et al.
JOURNAL OF NEUROLOGY (2016)
Effects of tafamidis treatment on transthyretin (TTR) stabilization, efficacy, and safety in Japanese patients with familial amyloid polyneuropathy (TTR-FAP) with Val30Met and non-Varl30Met: A phase III, open-label study
Ando Yukio et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2016)
Cerebral amyloid angiopathy in posttransplant patients with hereditary ATTR amyloidosis
Yoshiki Sekijima et al.
NEUROLOGY (2016)
Repositioning tolcapone as a potent inhibitor of transthyretin amyloidogenesis and associated cellular toxicity
Ricardo Sant'Anna et al.
NATURE COMMUNICATIONS (2016)
Peripheral Blood Cell Gene Expression Diagnostic for Identifying Symptomatic Transthyretin Amyloidosis Patients: Male and Female Specific Signatures
Sunil M. Kurian et al.
THERANOSTICS (2016)
Ophthalmological manifestations in hereditary transthyretin (ATTR V30M) carriers: a review of 513 cases
Joao Melo Beirao et al.
AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS (2015)
Neuroinflammation in Alzheimer's disease
Michael T. Heneka et al.
LANCET NEUROLOGY (2015)
Time for one-person trials
Nicholas J. Schork
NATURE (2015)
Knocking down disease: a progress report on siRNA therapeutics
Anders Wittrup et al.
NATURE REVIEWS GENETICS (2015)
Liver Transplantation for Hereditary Transthyretin Amyloidosis: After 20 Years Still the Best Therapeutic Alternative?
Bo-Goran Ericzon et al.
TRANSPLANTATION (2015)
Cardiac Findings and Events Observed in an Open-Label Clinical Trial of Tafamidis in Patients with non-Val30Met and non-Val122Ile Hereditary Transthyretin Amyloidosis
Thibaud Damy et al.
JOURNAL OF CARDIOVASCULAR TRANSLATIONAL RESEARCH (2015)
CNS involvement in V30M transthyretin amyloidosis: clinical, neuropathological and biochemical findings
Luis F. Maia et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2015)
Amyloid Cardiomyopathy in Hereditary Transthyretin V30M Amyloidosis - Impact of Sex and Amyloid Fibril Composition
Sandra Arvidsson et al.
PLOS ONE (2015)
Interleukin-1 signaling pathway as a therapeutic target in transthyretin amyloidosis
Nadia Pereira Goncalves et al.
AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS (2014)
Retrospective study of a TTR FAP cohort to modify NIS+7 for therapeutic trials
N. Suanprasert et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2014)
SILENCING OF MURINE TRANSTHYRETIN AND RETINOL BINDING PROTEIN GENES HAS DISTINCT AND SHARED BEHAVIORAL AND NEUROPATHOLOGIC EFFECTS
J. N. Buxbaum et al.
NEUROSCIENCE (2014)
Individual NSAIDs and Upper Gastrointestinal Complications
Jordi Castellsague et al.
DRUG SAFETY (2013)
Effect on disability and safety of Tafamidis in late onset of Met30 transthyretin familial amyloid polyneuropathy
P. Lozeron et al.
EUROPEAN JOURNAL OF NEUROLOGY (2013)
Repurposing Diflunisal for Familial Amyloid Polyneuropathy A Randomized Clinical Trial
John L. Berk et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2013)
Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy
Teresa Coelho et al.
JOURNAL OF NEUROLOGY (2013)
Antisense Oligonucleotides: Treating Neurodegeneration at the Level of RNA
Sarah L. DeVos et al.
NEUROTHERAPEUTICS (2013)
Safety and Efficacy of RNAi Therapy for Transthyretin Amyloidosis
Teresa Coelho et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
AG10 inhibits amyloidogenesis and cellular toxicity of the familial amyloid cardiomyopathy-associated V122I transthyretin
Sravan C. Penchala et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Effects of Tafamidis on Transthyretin Stabilization and Clinical Outcomes in Patients with Non-Val30Met Transthyretin Amyloidosis
Giampaolo Merlini et al.
JOURNAL OF CARDIOVASCULAR TRANSLATIONAL RESEARCH (2013)
Why are some amyloidoses systemic? Does hepatic chaperoning at a distance prevent cardiac deposition in a transgenic model of human senile systemic (transthyretin) amyloidosis?
Joel N. Buxbaum et al.
FASEB JOURNAL (2012)
The Transthyretin Amyloidoses: From Delineating the Molecular Mechanism of Aggregation Linked to Pathology to a Regulatory-Agency-Approved Drug
Steven M. Johnson et al.
JOURNAL OF MOLECULAR BIOLOGY (2012)
Tafamidis for transthyretin familial amyloid polyneuropathy A randomized, controlled trial
Teresa Coelho et al.
NEUROLOGY (2012)
Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade
Christine E. Bulawa et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Manifestations of transthyretin-related familial amyloidotic polyneuropathy: Long-term follow-up of Japanese patients after liver transplantation
Yuki Ohya et al.
SURGERY TODAY (2011)
Biochemical effect of liver transplantation in two Swedish patients with familial amyloidotic polyneuropathy (FAP-met30)
Gösta Holmgren et al.
CLINICAL GENETICS (2010)
Phenylketonuria: a 21(st) century perspective
Francjan J. van Spronsen
NATURE REVIEWS ENDOCRINOLOGY (2010)
Amyloid fibril composition is related to the phenotype of hereditary transthyretin V30M amyloidosis
E. Ihse et al.
JOURNAL OF PATHOLOGY (2008)
Transthyretin protects Alzheimer's mice from the behavioral and biochemical effects of Aβ toxicity
Joel N. Buxbaum et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
In vivo stabilization of mutant human transthyretin in transgenic mice
Clement E. Tagoe et al.
AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS (2007)
Accelerated Aβ deposition in APPswe/PS1ΔE9 mice with hemizygous deletions of TTR (transthyretin)
Se Hoon Choi et al.
JOURNAL OF NEUROSCIENCE (2007)
Orally administered diflunisal stabilizes transthyretin against dissociation required for amyloidogenesis
Yoshiki Sekijima et al.
AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS (2006)
Amyloid deposits in transthyretin-derived amyloidosis:: cleaved transthyretin is associated with distinct amyloid morphology
J Bergström et al.
JOURNAL OF PATHOLOGY (2005)
A different amyloid formation mechanism: De novo oculoleptomeningeal amyloid deposits after liver transplantation
Y Ando et al.
TRANSPLANTATION (2004)
Diflunisal analogues stabilize the native state of transthyretin. Potent inhibition of amyloidogenesis
SL Adamski-Werner et al.
JOURNAL OF MEDICINAL CHEMISTRY (2004)
Familial amyloid polyneuropathy: Receptor for advanced glycation end products-dependent triggering of neuronal inflammatory and apoptotic pathways
MM Sousa et al.
JOURNAL OF NEUROSCIENCE (2001)
Cardiac amyloid in patients with familial amyloid polyneuropathy consists of abundant wild-type transthyretin
M Yazaki et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2000)
分享论文
